Hammerstingl, Christoph <br/><br/>
How useful is determination of anti-factor Xa activity to guide bridging therapy with enoxaparin? A pilot study.  [electronic resource] 

 -  Thrombosis and haemostasis  Feb 2009 
 - 325-32 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article 
<br/><br/><label>ISSN: </label>0340-6245 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Anticoagulants--administration & dosage<br/>Drug Administration Schedule<br/>Drug Monitoring--methods<br/>Enoxaparin--administration & dosage<br/>Factor Xa Inhibitors<br/>Hemorrhage--chemically induced<br/>Humans<br/>International Normalized Ratio<br/>Linear Models<br/>Logistic Models<br/>Middle Aged<br/>Partial Thromboplastin Time<br/>Phenprocoumon--administration & dosage<br/>Pilot Projects<br/>Predictive Value of Tests<br/>Prospective Studies<br/>Risk Assessment<br/>Surgical Procedures, Operative--adverse effects<br/>Thromboembolism--etiology<br/>Treatment Outcome